Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280794 | 1.00 | GHSR (0.57) | GHSRALDH1A1MAPTMMEACE | |
| SCHEMBL3268292 | 1.00 | GHSR (0.57) | GHSRALDH1A1MAPTMMEACE | |
| SCHEMBL3266959 | 0.99 | GHSR (0.57) | GHSRALDH1A1MAPTMMEACE | |
| SCHEMBL3266966 | 0.99 | GHSR (0.57) | GHSRALDH1A1MAPTMMEACE | |
| SCHEMBL3266703 | 0.91 | GHSR (0.56) | GHSR | |
| SCHEMBL3266691 | 0.91 | GHSR (0.56) | GHSR | |
| SCHEMBL13308041 | 0.90 | GHSR (0.57) | GHSR | |
| SCHEMBL3266944 | 0.90 | GHSR (0.57) | GHSR | |
| SCHEMBL3266709 | 0.90 | GHSR (0.57) | GHSR | |
| SCHEMBL13307937 | 0.88 | GHSR (0.60) | GHSRALDH1A1MAPTF2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506969-B1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS US INC (US) | 2010-06-09 | — | — | EP | claimed |
| EP-1506969-A1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-02-16 | — | — | EP | claimed |
| EP-1047709-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-11-02 | — | — | EP | claimed |
| WO-1999036431-A9 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2000-07-27 | — | — | WO | claimed |
| US-6083908-A | TREATING MEDICAL DISORDERS RESULTING FROM DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2000-07-04 | — | — | US | claimed |
| WO-1999036431-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-07-22 | — | — | WO | claimed |
| EP-1506969-B1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS US INC (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1506969-A1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| EP-1047709-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-11-03 | — | — | EP | disclosed |
| EP-1047709-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036431-A9 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2000-07-27 | — | — | WO | disclosed |
| US-6083908-A | TREATING MEDICAL DISORDERS RESULTING FROM DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2000-07-04 | — | — | US | disclosed |
| WO-1999036431-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-07-22 | — | — | WO | disclosed |